Investigational drug · Phase 2
DDY391
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Moderate to Severe Psoriatic Arthritis, Sjögren's Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
3
Any phase or sponsor naming "DDY391"
First trial start
2026
Aug 24, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DDY391", any sponsor or status.
Conditions studied
As listed on its trial records.
- Moderate to Severe Psoriatic Arthritis
- Sjögren's Disease
Approved drugs for the same conditions: Psoriatic arthritis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "DDY391" as an intervention, largest first.
- A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's DiseasePivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07737743 · 344 participants (planned) · Start Aug 24, 2026 · Primary completion Feb 19, 2029
Drug: DDY391; Placebo · For: Sjögren's Disease
Sites: Avondale, Arizona; Clearwater, Florida; Tampa, Florida · 31 sites in all
- A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic ArthritisPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07801495 · 220 participants (planned) · Start Oct 19, 2026 · Primary completion Dec 13, 2028
Drug: DDY391; Placebo · For: Moderate to Severe Psoriatic Arthritis
Sites: Huntington Beach, California; Duncansville, Pennsylvania; Philadelphia, Pennsylvania · 8 sites in all
- Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)Not yet recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07923773 · 88 participants (planned) · Start Feb 10, 2027 · Primary completion Dec 12, 2029
Drug: DDY391 · For: Moderate to Severe Psoriatic Arthritis
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.